Aralez Pharmaceuticals (ARLZ) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) in a research note released on Monday, Marketbeat reports. The firm issued a buy rating and a $6.00 price target on the stock.

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at $1.68 on Monday. The company has a debt-to-equity ratio of 4.64, a quick ratio of 0.92 and a current ratio of 1.00. The firm has a market capitalization of $116.38, a price-to-earnings ratio of -1.00 and a beta of 1.44. Aralez Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $4.65.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company had revenue of $24.30 million during the quarter, compared to the consensus estimate of $22.87 million. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%. The firm’s quarterly revenue was up 78.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.32) EPS. research analysts forecast that Aralez Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

In other news, Director Arthur S. Kirsch purchased 50,000 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was bought at an average price of $1.47 per share, for a total transaction of $73,500.00. Following the purchase, the director now owns 271,609 shares of the company’s stock, valued at $399,265.23. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its stake in Aralez Pharmaceuticals by 151.5% in the 4th quarter. Wells Fargo & Company MN now owns 686,931 shares of the company’s stock worth $975,000 after purchasing an additional 413,801 shares during the period. Brown Advisory Securities LLC bought a new position in Aralez Pharmaceuticals in the 3rd quarter worth about $394,000. Finally, Ballentine Partners LLC boosted its stake in Aralez Pharmaceuticals by 166.7% in the 3rd quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock worth $183,000 after purchasing an additional 50,000 shares during the period. Institutional investors own 19.45% of the company’s stock.

WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit